Cystic Fibrosis – CF-EU2

Cystic Fibrosis (CF) is the most common life-limiting autosomal recessive disorder in the Caucasian population.

Yourgene CF-EU2v1 kit is used for diagnosis of quistic fibrosis through qualitative detection of the most common CFTR gene mutations found in european population in DNA extracted from whole blood (EDTA preserved) and dried bloodspot samples​.  

The assay identifies 50 mutations in total and also analyzes intron 8 polyT tract with accurate measurement of the adjacent TG repeat. Can distinguish between individuals who are heterozygous and homozygous for the all mutations and variants with the exception of S549R(T>G).

For maximum coverage in the diagnosis of cystic Fibrosis, Yourgene CF-EU2 kit can be combined with the Iberian Panel  kit (12 additional mutations).

CFTR gene mutations have also been associated with male infertility problems such as Congenital Unilateral Absence of the Vas Deferens (CUAVD) and Congenital Bilateral Absence of the Vas Deferens (CBAVD), so Elucigene CF-EU2 kit also provides a useful screening tool for these diseases. (More kits for diagnostic of male infertility, here)

SPECIFICATIONS

Due to the nature of the design of the CF-EU2v1 kit the presence of insertions or deletions between two opposing primers will result in size changes to all the amplicon produced between these two primers.

Therefore, in addition to the 50 mutations detected by the CF-EU2v1 kit, any insertions and deletions within the amplified target sequences can be detected by the change in expected amplicon size in the wild type (B) mix.

Area:

Cystic fibrosis, Molecular Genetics

Technology:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SOPHiA DDM GEN2

Analytical platform for clinical genomics that enables the detection, annotation, and interpretation of genomic variants using artificial intelligence to support patient diagnosis and treatment. Detailed Description SOPHiA DDM™ Platform is an advanced solution for precision medicine workflows, with a renewed interface, web access, and new functionalities to accelerate genomic data analysis. It offers end‑to‑end workflows…
SOPHIA Genetics

PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements)

PGT‑SR (Preimplantation Genetic Testing for Structural Chromosomal Rearrangements) is a solution aimed at the analysis of structural chromosomal rearrangements in embryos. According to the product literature, it is based on single‑cell whole‑genome amplification and NGS sequencing to detect embryos from patients with chromosomal abnormalities and select euploid embryos for transfer, with the aim of reducing…
Yikon Genomics
Next Generation Sequencing (NGS)

MaReCs (Mapping allele with resolved carrier state test)

MaReCs® (Allelic Mapping with Resolved Carrier Status) is a PGT‑SR technology that first identifies aneuploid or euploid embryos and then analyses translocation breakpoints and SNP linkage to differentiate carrier from non‑carrier euploid embryos. Detailed Description Principle of operation MaReCs® combines ChromSwift® technology with NGS sequencing to perform a CNV analysis and subsequently an SNP linkage…
Yikon Genomics
Next Generation Sequencing (NGS)

KaryoSeq (Integrated solution for PGT-M, PGT-SR and PGT-A)

KaryoSeq™ is a next‑generation sequencing (NGS)‑based solution for preimplantation genetic testing that enables PGT‑M, PGT‑SR and PGT‑A within a single workflow. It is designed for the analysis of DNA extracted from 3 to 10 trophectoderm cells of human embryos at the blastocyst stage. Detailed Description Principle of operation KaryoSeq™ is based on the MARSALA principle…
Yikon Genomics
Next Generation Sequencing (NGS)